News

Filter

1 to 9 of 27 results

EULAR: Sustained outcomes with UCB’s Cimzia in spondyloarthritis

EULAR: Sustained outcomes with UCB’s Cimzia in spondyloarthritis

12-06-2014

Belgium’s leading drugmaker UCB today presented new long-term data on Cimzia (certolizumab pegol) in…

Anti-Arthritics/RheumaticsBiotechnologyCimziaResearchUCB

Sanofi and UCB in immune-mediated diseases research partnership

Sanofi and UCB in immune-mediated diseases research partnership

11-03-2014

French pharma major Sanofi and UCB, Belgium’s largest drugmaker, have entered into a scientific and…

Anti-Arthritics/RheumaticsGastro-intestinalsImmunologicalsPharmaceuticalResearchSanofiUCB

Product launches to fuel lupus market growth

28-02-2014

The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

Amgen and UCB’s romosozumab shows significant increase in BMD

Amgen and UCB’s romosozumab shows significant increase in BMD

02-01-2014

US biotech firm Amgen and partner UCB of Belgium have announced positive results from a Phase II trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyForteoFosamaxResearchromosozumabUCB

UCB’s Cimzia granted additional indication by US FDA

UCB’s Cimzia granted additional indication by US FDA

30-09-2013

UCB revealed today that the US Food and Drug Administration has approved its currently marketed drug…

Anti-Arthritics/RheumaticsCimziaNorth AmericaPharmaceuticalRegulationUCB

Russia's R-Pharm to develop UCB's olokizumab for rheumatoid arthritis

04-07-2013

Belgium's leading pharma company UCB (Euronext Brussels: UCB) said today (July 4) that it has granted…

Anti-Arthritics/RheumaticsLicensingolokizumabPharmaceuticalR-PharmaRoActemraRocheUCB

AbbVie/Eisai's Humira has best clinical profile among psoriatic arthritis treatments

03-06-2013

Based on clinical data and the opinions of interviewed thought leaders interviewed by health care advisory…

AbbVieAnti-Arthritics/RheumaticsAstellas PharmaBiotechnologyCimziaEisaiEuropeHumiraMarkets & MarketingNorth AmericaPharmaceuticalUCB

Thought leader views on new osteoporosis and osteopenia treatments

05-04-2013

US and European primary care physicians (PCPs) agree that efficacy on hip fracture risk reduction is…

AMG-785AmgenAnti-Arthritics/RheumaticsBiotechnologyCDP-7851Eli LillyEuropeHealthcareMarkets & MarketingMerck & CoNorth AmericaodanacatibPharmaceuticalteriparatideUCB

1 to 9 of 27 results

Back to top